How bad was that original risk-share? Sanofi had to threaten to remove their therapy from the PBS for atopic dermatitis to secure any changes, and it remains so bad that Lilly is not going to list EBGLYSS. …
This could be the canary in the coal mine, but a lot of canaries have already died
June 15, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
New Zealand's pre-election Budget boosts health spending, but Pharmac misses out
May 29, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 29 May
May 28, 2026 - - Podcast -
AusBiotech unites conferences under the banner of the 'Biggest Week' in biotech
May 28, 2026 - - Australian Biotech -
Research highlighting gaps leaving some communities at greater risk as flu
May 28, 2026 - - Latest News -
A fraught process but also an opportunity to reintroduce ideas sidelined by the review
May 28, 2026 - - Latest News -
Single infusion of Lilly gene editing cuts cholesterol with the company planning long-term study
May 27, 2026 - - Latest News -
ARCS launches national partnership to boost public clinical research sites
May 27, 2026 - - Latest News